The compound was synthesized for Cerepeut Inc. by the Chemistry Branch of Medicilon.

Part of the compound synthesis was performed at Medicilon.

BAY-1834845 and PF-06650833 are synthesize by Medicilon.

Pharmacokinetics, toxicokinetics and anti-drug antibodies of YYB-101 in cynomolgus monkeys were conducted by the Test and Control Article Department of Medicilon Preclinical Research, LLC, in accordance with regulations outlined in the USDA Animal Welfare

CDX studies were performed at Shanghai Medicilon (OS-RC-2). All studies were performed in accordance with animal research guidelines from the Shanghai Medicilon Inc.

Recombinant proteins were synthesized and purified by Medicilon

The experiments (Rat colon distension model of IBS-d) were carried out by Medicilon. The protocol complied with and was approved by the Institutional Animal Care and Use Committee and Medicilon is accredited by the NIH Office of laboratory Animal Welfare

Butenolide with a purity >99% was synthesized by Medicilon.

The flowcytometry (FCM)-based immune profiling panel studies in J558 allograft syngeneic mouse models were performed at Medicilon. In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies w

6月5日，美迪西云講堂特邀藥理部副主任，AACR Poster Auther張巍鐘博士，結(jié)合一線研發(fā)經(jīng)驗(yàn)，從前沿進(jìn)展到創(chuàng)新實(shí)踐，帶來(lái)直播《類器官技術(shù)賦能腫瘤藥理創(chuàng)新應(yīng)用》

五月美迪西將主辦2場(chǎng)線上直播，同時(shí)參與Swiss Biotech Day 2025、PEGS Boston 2025、APT 2025 3場(chǎng)海外會(huì)議，期待與各位業(yè)內(nèi)同仁交流分享藥物研發(fā)新趨勢(shì)。

美迪西作為濟(jì)煜醫(yī)藥的長(zhǎng)期合作伙伴，依托抗體藥物研發(fā)服務(wù)平臺(tái)，為JYB1904提供了符合GLP規(guī)范的（包括藥代和安全性評(píng)價(jià)在內(nèi)的）綜合性臨床前研究服務(wù)，共同推進(jìn)了研發(fā)進(jìn)程。

美迪西與臺(tái)灣研發(fā)型生技新藥發(fā)展協(xié)會(huì) (TRPMA) 攜手，將于12月16日下午共同舉辦「New Approaches to Facilitate Drug Discovery and Development」新藥研發(fā)論壇，內(nèi)容涵蓋ADC與核酸藥物的研發(fā)進(jìn)展、毒理學(xué)策略等。

美迪西藥學(xué)研究事業(yè)部副總裁李文捷博士受邀出席BioForward 2024會(huì)議，并主持研討會(huì)“Partnering with the Right R&D Service Provider to Accelerate Your Research”。

資本市場(chǎng)顛撲不破的真理是價(jià)值回歸，從量變到質(zhì)變的中國(guó)創(chuàng)新也逐漸見(jiàn)成效，促使license-out交易持續(xù)出現(xiàn)。寒冬下新藥研發(fā)依然不乏新的突破和亮眼的臨床數(shù)據(jù)。未滿足的臨床需要，才是biotech穿越市場(chǎng)波動(dòng)，穩(wěn)健前行的北斗星。2024年9月14日，BioSpark將舉辦首屆年會(huì)。會(huì)議主題為“Braving through the Winter of Biotech”。本次年會(huì)匯聚了來(lái)自全球生物行業(yè)

12月5日，在Genesis 2023期間，美迪西與倫敦 MHA 聯(lián)合主辦Genesis Fringe Seminar。主題為：A UK-China Approach to Developing the Right Strategies for Early-stage Life Science Company Growth。

2023年9月30日中秋佳節(jié)，南加生物醫(yī)學(xué)和制藥促進(jìn)會(huì) (SABPA)成功舉辦了第21屆圣地亞哥生物制藥論壇，陳春麟博士受邀發(fā)表了“Retrospective Studies on New Drug Research in China based on IND Approval Cases at Medicilon”精彩演講。

美迪西創(chuàng)始人&CEO陳春麟博士將出席第21屆圣地亞哥生物制藥大會(huì)，并帶來(lái)主題演講：“Retrospective Studies on New Drug Research in China based on IND Approval Cases at Medicilon”

美迪西團(tuán)隊(duì)將參加2023年應(yīng)用藥物分析研討會(huì)，并帶來(lái)“The Boost of ADMET, PK and Bioanalysis for Drug Discovery and Development”（ADMET、PK和生物分析對(duì)藥物研發(fā)的推動(dòng)作用）精彩海報(bào)。

第57屆歐洲毒理學(xué)家和歐洲毒理學(xué)會(huì)大會(huì)（57TH CONGRESS OF THE EUROPEAN SOCIETIES OF TOXICOLOGY，EUROTOX 2023）大會(huì)安排了一系列精彩的學(xué)術(shù)內(nèi)容，美迪西精選了重點(diǎn)報(bào)告信息，供您參考。